Market Overview

Ahead Of Earnings: Why You Should Be Buying Merck And Selling Bristol-Myers

Share:
Ahead Of Earnings: Why You Should Be Buying Merck And Selling Bristol-Myers
Related BMY
Ultragenyx Seeks An FDA Win For Biologic Therapy Candidate
Analyst: Nektar Has A Handful Of Milestones Ahead In 2018
Roche Rocks On With More Good News (Seeking Alpha)
Related MRK
Merck Revisits Low Of Move And Rebounds
Pharma ETFs Down Post Q3 Earnings
Stocks Close Modestly Higher As Verizon Helps Prop Up The Dow (Investor's Business Daily)

Pharmaceutical giants Bristol-Myers Squibb Co (NYSE: BMY) and Merck & Co., Inc. (NYSE: MRK) both release their second quarter earnings reports this week.

According to BMO Capital, investors should be buying Merck and selling Bristol-Myers ahead of earnings.

Despite Merck being on the verge of five years of delivering solid growth, BMO analyst Alex Arfaei believes that some of the company’s assets are still under-appreciated.

Cancer immunotherapy drug Keytruda is seeing a significant increase in use, from 20 percent reported use, up from around 3 percent use in April, and could see $12 billion in sales by 2026. BMO is forecasting Keytruda to deliver $3.7 billion in sales in 2017.

BMO maintains an Outperform rating on Merck but lowered its price target from $74 to $73 (see Arfaei's track record here).

While Arfaei is expecting a solid second quarter for Bristol-Myers Squibb, he expects uncertainty and headwinds ahead.

It appears that the increase in use of Keytruda is a positive for Merck and is directly impacting Bristol-Myers.

“Our surveyed oncologist reported using Keytruda in ~40% of 1L patients in July. We view this as a positive leading indicator for MRK and negative for BMY,” said Arfaei in a new analyst note.

Given the expectations for increased uncertainty, the analyst believes that a takeover/merger seems less likely, and if it does ultimately end up happening, the takeout premium appears to be lower.

BMO maintains an Underpeform rating on Bristol-Myers with a $47 price target.

Related Links:

Opdivo News Doesn't Give Bristol-Myers Much Of A Boost

Barron's Picks And Pans: Bristol-Myers, Texas Instruments, Altaba And More

Latest Ratings for BMY

DateFirmActionFromTo
Oct 2017Credit SuisseMaintainsNeutral
Oct 2017Leerink SwannMaintainsOutperform
Oct 2017CitigroupMaintainsBuy

View More Analyst Ratings for BMY
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Earnings Long Ideas News Short Ideas Health Care Previews Best of Benzinga

 

Related Articles (BMY + MRK)

View Comments and Join the Discussion!

Partner Center